Too often, patients with chronic kidney disease get diagnosed too late – if at all. Addressing risk factors early can stave ...

Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

José Gregorio González came to the U.S. to save his brother, who is in kidney failure. But now he faces deportation, which ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision ...

Research led by Children's Hospital of Fudan University in China has found that a gene called pancreatic progenitor cell ...

Deficiency of the pancreatic progenitor cell differentiation and proliferation factor gene was identified as a risk factor ...

For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people who have it are formally diagnosed. The consequences of advanced ...

Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...

Prof Mignon McCulloch delivered the second inaugural lecture of the year at UCT last week, focusing on kidney diseases in Africa and beyond.

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...